GE HealthCare’s International RadNet Deal Shows Imaging AI Is Going Global
GE HealthCare is expanding its partnership with RadNet beyond the U.S., signaling that imaging AI is moving from domestic pilots into international commercialization. The deal underscores how vendor partnerships are becoming central to the race to scale AI across imaging networks.
The expansion of GE HealthCare’s partnership with RadNet is notable because it suggests the imaging AI market is now being organized around distribution as much as innovation. The hard part is no longer only building an algorithm; it is getting it embedded across large networks with consistent workflow, regulatory, and reimbursement support.
RadNet has become an important proving ground for breast imaging AI, and GE HealthCare’s decision to widen the relationship internationally implies confidence that the model can travel. That matters because global adoption often exposes the limits of a product that works well in a single mature market but struggles with variation in practice patterns, infrastructure, and procurement.
This is also a sign that imaging AI is evolving into a platform business. Partnerships with large networks allow vendors to gather data, refine products, and create a broader commercial footprint. In return, health systems get access to tools that may improve detection and efficiency while reducing the burden of building their own AI ecosystems.
The open question is whether these collaborations translate into durable clinical value or simply market share gains. If the partnership delivers measurable improvements in outcomes, access, and productivity, it could become a template for how imaging AI scales beyond flagship deployments.